Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)

被引：0
|
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL 33407 USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication
    Winner, Paul K.
    Singh, Rashmi B. Halker
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [2] Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
    Winner, Paul
    Singh, Rashmi Halker
    Cohen, Joshua
    Yang, Ronghua
    Yeung, Paul
    Campos, Verena Ramirez
    NEUROLOGY, 2019, 92 (15)
  • [3] Impact of Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
    Silberstein, Stephen
    Ailani, Jessica
    Cohen, Joshua
    Yang, Ronghua
    Yeung, Paul P.
    Campos, Verena Ramirez
    NEUROLOGY, 2019, 92 (15)
  • [4] Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication
    Silberstein, Stephen D.
    Ailani, Jessica
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [5] Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication
    McAllister, Peter
    Dodick, David
    Cohen, Joshua
    Yang, Ronghua
    Yeung, Paul
    Campos, Verena Ramirez
    NEUROLOGY, 2019, 92 (15)
  • [6] Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication
    McAllister, Peter
    Dodick, David W.
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [7] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
    Brandes, Jan L.
    Smith, Timothy R.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Carr, Karen
    CEPHALALGIA, 2019, 39 : 233 - 233
  • [8] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    Brandes, J.
    Smith, T. R.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 119 - 120
  • [9] Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication (vol 19, pg O40, 2018)
    McAllister, Peter
    Dodick, David W.
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [10] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    McAllister, P.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 119 - 119
12345